The Pharma Data

NOVEMBER 2, 2020

million people were treated for lymphatic filariasis (LF) in 38 countries that implemented mass drug administration (MDA) of populations at risk of the disease, as recommended by the World Health Organization (WHO). million people no longer require MDA for this debilitating parasitic disease. Setting sights on 2030.

Packaging 52

Packaging Disease Treatment Drugs 52

The Pharma Data

APRIL 7, 2021

Thirty of Sanofi’s medicines will be provided across a wide range of therapeutic areas, including cardiovascular disease, diabetes, tuberculosis, malaria and cancer. In December 2020, Sanofi announced it had renewed its five-year partnership with WHO to fight neglected tropical diseases that affect approximately one billion people.

Vaccine 52

Vaccine Packaging Disease Treatment 52

The Pharma Data

OCTOBER 29, 2020

Scaling up efforts on the prevention and control of non-communicable diseases (NCDs) can avert over 4.3 These immense benefits can be achieved through investment in five proven and cost-effective intervention packages recommended by WHO to address the major NCD risk factors. . million deaths and yield RUB 8.1

Disease 40

Disease Packaging Government Production 40

The Premier Consulting Blog

MAY 4, 2023

billion in 2022 and is expected to grow approximately eight percent from 2023 to 2030 [1]. The new guidance provides detailed information to applicants and manufacturers regarding compliance with the requirements in 21 CFR Part 4 for ophthalmic drugs packaged with eye cups, eye droppers, or other dispensers. Regulatory Focus.

FDA 52

FDA Packaging Regulations Compliance 52

Codon

MARCH 24, 2024

In the case of semaglutide, those cells are Saccharomyces cerevisiae— also known as Baker’s yeast — engineered to secrete a peptide precursor that is later purified, chemically modified, packaged into an injectable or tablet form, and then shipped around the world. Continuing this method may not scale.

Engineering 85

Engineering Vaccine Production RNA 85

The Pharma Data

NOVEMBER 5, 2020

This quarter we had robust top- and bottom-line growth driven by EYLEA in retinal diseases and Dupixent in atopic dermatitis and asthma. Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. About Regeneron Pharmaceuticals, Inc.

Production 40

Production FDA Trials FDA Approval 40

The Pharma Data

OCTOBER 18, 2020

Mitigating the impact of COVID-19 on essential HIV, hepatitis and STI services; Proposing key elements, themes and principles for 2022-2030 strategies; Balancing the need for disease specificity and sustainability in health including through universal health coverage, primary healthcare and health systems strengthening; and.

Packaging 52

Packaging Disease Science Drugs 52